Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease

Overseen By Michael Khoury, MD

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: University of Alberta

Disqualifiers: Non-English, Arrhythmias, Cognitive impairment, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

20 Participants Needed

Trial Summary

What is the purpose of this trial?

There are many barriers to heart-healthy lifestyles in pediatric patients with acquired and congenital heart disease. Investigators want to further understand how participants heart and skeletal muscles work together during exercise and evaluate the impact on cardiac function. To do this, the investigators will use magnetic resonance imaging (MRI) to scan the heart and skeletal muscles during exercises to assess blood flow, oxygenation and function.

Research Team

Michael Khoury, MD

Principal Investigator

University of Alberta

Eligibility Criteria

Inclusion Criteria

I am between 10 and 18 years old and am a patient at Stollery Children's Hospital.

I received a heart transplant more than 6 months ago.

I have been diagnosed with a moderate to complex heart condition from birth.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants undergo cardiopulmonary exercise testing and resting cardiac MRI

1 day

1 visit (in-person)

Exercise MRI Assessment

Participants complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer

1 day

1 visit (in-person)

12-week HIIT Exercise Protocol

Participants undergo a 12-week high-intensity interval training exercise protocol

12 weeks

Follow-up

Participants are monitored for changes in cardiac and skeletal muscle MRI measures

4 weeks

Treatment Details

Participant Groups

Group I: Heart transplant recipient Experimental Treatment 2 Interventions

Participants aged 10-18 years who have recieved a heart transplant.

Group II: Congenital heart disease Experimental Treatment 2 Interventions

Participants aged 10-18 years who have congenital heart disease.

Who Is Running the Clinical Trial?

University of Alberta

Lead Sponsor

Trials

957

Recruited

437,000+